Home > Boards > US Listed > Medical - Drugs > Cerus Corporation (CERS)

From Berkshire Hathaway's - Business Wire

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mogman Member Profile
 
Followed By 12
Posts 471
Boards Moderated 0
Alias Born 04/14/13
160x600 placeholder
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/29/2020 4:05:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/28/2020 4:10:02 PM
Cerus Corporation Announces FDA PMA Supplement Submission for Pathogen-Reduced Cryoprecipitated Fibrinogen Complex Business Wire - 5/26/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 6:23:37 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/5/2020 5:29:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2020 4:05:04 PM
Cerus Corporation Announces First Quarter 2020 Results Business Wire - 5/5/2020 4:01:00 PM
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Plasma with Alternate Plastic Disposable Kits Business Wire - 5/4/2020 8:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/24/2020 12:06:16 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/24/2020 12:02:44 PM
Cerus Corporation to Release First Quarter 2020 Financial Results on May 5, 2020 Business Wire - 4/24/2020 8:30:00 AM
Cerus Corporation Announces Expansion of BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells Business Wire - 4/20/2020 5:50:00 PM
Cerus Corporation Provides Update on COVID-19 Related Activities Business Wire - 4/6/2020 8:30:00 AM
Cerus Corp. Announces the Inclusion of Pathogen Reduction Technology in the ISBT Working Party Recommendations for the Prepar... Business Wire - 4/2/2020 8:30:00 AM
University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent... Business Wire - 4/2/2020 8:30:00 AM
Cerus Forms Group to Research Optimal Production of COVID-19 Convalescent Plasma Business Wire - 3/26/2020 8:30:00 AM
Unknown (sec Staff) Edgar (US Regulatory) - 3/24/2020 1:40:08 PM
Unknown (sec Staff) Edgar (US Regulatory) - 3/24/2020 1:39:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/6/2020 6:13:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2020 4:15:15 PM
Cerus Corporation Announces Strategic Organizational Changes Business Wire - 3/2/2020 4:10:00 PM
Cerus Corporation to Participate in Upcoming Investor Conferences Business Wire - 2/25/2020 8:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 2/21/2020 4:22:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/20/2020 4:09:21 PM
Cerus Corporation Announces Record Fourth Quarter and Full Year 2019 Financial Results Business Wire - 2/20/2020 4:01:00 PM
mogman   Saturday, 03/10/18 11:52:26 AM
Re: None
Post # of 323 
From Berkshire Hathaway's - Business Wire

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and year ended December 31, 2017.

Recent developments and highlights include:

*Reported record fourth quarter product revenue of $16.2 million, an increase of 60% compared to the
same period in the year prior.
*Established 2018 annual product revenue guidance of $51 million to $53 million, which would
represent a

17% to 22% increase over 2017 reported product revenue.

*Successfully met primary safety and efficacy endpoints in SPARC, Cerus’ European Phase 3 clinical trial *evaluating INTERCEPT red cell transfusions in thalassemia patients.
*Completed an underwritten public offering of common stock raising gross proceeds of $57.5 million.
*Advanced release assay for commercial manufacturing of the S303 compound used in the INTERCEPT
red blood cell system to enable H2 2018 CE Mark submission.

IMO it is up from here and a buy at $5.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist